Group 1 - Company has been actively repurchasing shares, with a recent buyback on October 21 amounting to 340,000 HKD for nearly 60,000 shares [1] - Since September 26, the company has completed 7 buybacks, totaling over 20.3 million HKD [1] - As of October 21, the company's stock price closed at 5.69 HKD, reflecting a 1.07% increase [1] Group 2 - The company recently launched "Doctor Clinical Copilot," which has developed 25 intelligent scenarios, enabling a full process from intelligent medical record generation to patient education and smart care [1] - The self-developed "Yidu Big Model" and intelligent solutions have been implemented in over 110 hospitals nationwide [1]

Group 1 - The advanced manufacturing and artificial intelligence sectors are experiencing significant investment activity, with advanced manufacturing attracting 9 financing rounds totaling approximately 1.16 billion RMB and AI securing 6 rounds amounting to about 350 million RMB [2] - The total number of financing events in the domestic primary market from October 13 to October 19 was 29, with 20 disclosing amounts, summing up to around 2.265 billion RMB [1][2] Group 2 - The most active regions for financing were Beijing, Shanghai, Guangdong, and Zhejiang, with 8, 6, 4, and 4 financing events respectively [3] - Notable active investment institutions included Shunxi Fund, GF Xinde, and Qiming Venture Partners, each completing 2 financing rounds primarily in technology, manufacturing, and healthcare sectors [4] Group 3 - Velotric, a brand under Shenzhen Weile Technology Co., Ltd., completed a B round of financing led by Shunwei Capital [5][6] - Beijing Lingchuang Medical Valley Technology Development Co., Ltd. announced nearly 200 million RMB in B round financing, co-led by Shunxi Fund and Yizhuang Guotou [9][10] - Huadao Biopharmaceutical Co., Ltd. successfully completed over 100 million RMB in D++ round financing led by Boai New Open Source [15][16] Group 4 - VOLANT, a developer of electric vertical takeoff and landing aircraft, completed a B round financing of several hundred million RMB led by Huaying Capital [28][29] - Tianjin Shexu Technology Co., Ltd. secured several million RMB in Pre-B round financing, with funds allocated for R&D and market promotion [22][23] - Hunan Yanhe Technology Co., Ltd. announced over 100 million RMB in A round financing, aimed at building production lines for perovskite solar cells [52][53]

Core Viewpoint - The recent development of a 3D micro-nano robot by the Chinese Academy of Sciences represents a significant advancement in medical technology, enabling the possibility of non-invasive treatments for diseases such as cancer [1] Group 1: Technology Overview - The micro-nano robot is designed as a pair of flexible "mechanical hands" capable of performing precise tasks such as cell manipulation and particle release [1] - Measuring approximately 40 micrometers, the robot is smaller than a human hair, showcasing its advanced miniaturization [1] - It features a magnetic drive module that allows it to navigate through the micro-world by responding to external magnetic fields, akin to a compass [1] Group 2: Functional Characteristics - The robot exhibits a unique property of closing its "hands" in acidic environments and opening them in alkaline conditions, allowing for automatic operation without human intervention [1] - This adaptability enhances its potential for targeted drug delivery and precise cancer cell targeting without the need for invasive procedures [1] Group 3: Future Implications - The development of this micro-nano robot signifies a step towards realizing the dream of "nano-doctors" that can treat diseases internally, potentially revolutionizing the field of medical treatment [1]

Core Insights - The Abu Dhabi Department of Health launched the "Smart Population Health Analytics Platform" at GITEX Global 2025, marking a significant advancement in population health management through AI [1] Group 1: Platform Development - The platform is a collaboration between the Abu Dhabi Department of Health and Microsoft, integrating clinical, environmental, and lifestyle data [1] - It establishes a digital twin health model to enhance health management capabilities [1] Group 2: Functional Capabilities - The platform enables risk prediction, trend analysis, and intervention assessment, facilitating a proactive approach to health management [1] Group 3: Industry Impact - This initiative represents a crucial milestone in the UAE's healthcare system, transitioning towards a preventive care model [1]

新华财经香港10月21日电（记者林迎楠）由江苏省地方金融管理局和江苏省港澳办主办的"苏港金融投资合作交流会"20日在香港举行。来自江苏省的25家拟 在港上市及已在港上市企业主要负责人与香港金融服务机构及境外投资机构、基石投资人约160人就上市展开交流。 ky i 0 @ @ 图为江苏省地方金融管理局与香港特区政府财经事务及库务局签署合作备忘录（主办方供图） 在活动交流环节，华泰证券、江苏银行与高投集团分别就服务苏港两地资本对接与科创合作进行宣介。江苏企业上市香港服务基地也在会上正式揭牌，苏州 元禾钟山QDLP基金合作项目、华泰国际与多家江苏拟上市企业分别完成签约，达成多项合作意向。港股上市企业江苏恒瑞医药股份有限公司与英诺赛科 （苏州）科技股份有限公司也分享了各自的上市经验。 此外，路演环节中，来自智能制造、半导体、医疗科技等领域的江苏企业集中展示发展潜力，进一步推动苏港产融资源精准对接。 （文章来源：新华财经） 图为苏港金融投资合作交流会现场（主办方供图） 江苏省副省长赵岩致辞表示，长期以来，香港不仅为江苏带来丰厚的发展资金，更有先进技术管理经验和市场机会。两地不断深化拓展多领域合作，形成了 苏港经济发展相 ...

最近一周医渡科技已累计进行4次回购，合计回购约275.1万股，累计回购金额超过1600万港元。若将时 间线拉长至9月26日起，该股已完成6次回购，累计回购金额近2000万港元。 市场资金动向方面，据Wind最新数据，南向资金10月15日净买入医渡科技357.62万股，占当日成交量比 例为32.24%。从增减持金额来看，以增减持数量和成交均价为基准进行测算，南向资金当日净买入医 渡科技2113.53万港元，连续4日净买入，累计净买入7807万港元。 智通财经APP获悉，根据医渡科技(02158)最新公告，公司于10月20日再次回购股份，单日斥资37万港元 购回6.62万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年10月20日，该公司斥资37.23万港元回购6.62万股 股份，每股回购价格为5.59-5.65港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Yestar Healthcare Holdings Company Limited 巨星醫療控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2393） 自願公告 本公告由巨星醫療控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）自願 發表，旨在向本公司股東及潛在投資者提供有關本集團最新業務發展之最新消息。 可能成立合營企業及業務計劃 本公司董事（「董事」）會（「董事會」）謹此提供最新消息，本公司現正考慮與New Genetron Holding Limited（「Genetron Health」）於新加坡成立合營企業（「建議合營 企業」），並可能在印尼、馬來西亞及新加坡發展業務。 按照現時計劃，建議合營企業將於印尼註冊成立一間新實體，將專門從事設計、建 設及經營以精準腫瘤學為重心的臨床分子診斷實驗室，並在適當情況下，在當地建 立體外診斷試劑及試劑套裝的生產設施。換而言之，建議合營企 ...

记者从陆军军医大学新桥医院（以下简称"新桥医院"）获悉，该院联合重庆大学计算机学院，经过半年 多协同攻关，于日前成功研发出肺部感染疾病的人工智能专病大模型。这是国内首个基于诊疗策略生成 的肺部感染专病大模型。目前，该模型已部署至新桥医院呼吸病区医护工作站，进入临床试用阶段。 （文章来源：科技日报） 新桥医院呼吸与危重症医学中心主任徐智介绍，肺部感染作为一种常见却极具挑战性的疾病，每年全球 新增病例数亿，死亡人数超过百万。其病因复杂，表现多样，给临床诊断和治疗带来很大困难。对老年 人、孕产妇等特殊人群以及病情复杂的患者来说，医生在制定治疗方案时往往面临巨大挑战。 该模型聚焦肺部感染诊疗痛点，整合12893例高质量临床病例与包含43万余条问答的国内外权威医学指 南，为肺部感染疾病诊疗提供智能解决方案。在技术实现过程中，团队摒弃传统方法，结合多种训练策 略，使模型能更精准地理解医学问题，提供个性化诊疗建议。 新桥医院信息科主任陈学涛介绍，团队建立了"文本相似度+医疗关键点覆盖"的立体评测体系，该模型 在多项测试中表现出色。与当前国内外先进的通用大模型相比，这款模型在肺部感染疾病诊断准确性和 治疗方案推荐合理性上均有 ...

Core Points - The company has changed its investor contact number to improve investor relations management [1] - The new investor contact number is 021-60430629, replacing the old number 021-60430840 [1] - Other contact information, such as the company's registered address and email, remains unchanged [1]